EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Organovo Holdings's enterprise value is $7.90 Mil.
Organovo Holdings's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was $-19.50 Mil. Therefore, Organovo Holdings's EV-to-EBITDA for today is -0.40.
The historical rank and industry rank for Organovo Holdings's EV-to-EBITDA or its related term are showing as below:
ONVO'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -24.38 Med: -2.91 Max: 44.82
Current: -0.4
During the past 12 years, the highest EV-to-EBITDA of Organovo Holdings was 44.82. The lowest was -24.38. And the median was -2.91.
ONVO's EV-to-EBITDA is ranked worse than 100% of 469
companies
in the Biotechnology industry
Industry Median: 9.16
vs ONVO: -0.40
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
As of today (2024-04-19), Organovo Holdings's stock price is $1.13.
Organovo Holdings's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $-2.170. Therefore, Organovo Holdings's PE Ratio for today is At Loss.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.
Organovo Holdings EV-to-EBITDA Historical Data
The historical data trend for Organovo Holdings's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
Organovo Holdings Annual Data
Trend
Mar14
Mar15
Mar16
Mar17
Mar18
Mar19
Mar20
Mar21
Mar22
Mar23
EV-to-EBITDA
-3.29
-1.29
-2.75
-0.55
-0.28
Organovo Holdings Quarterly Data
Mar19
Jun19
Sep19
Dec19
Mar20
Jun20
Sep20
Dec20
Mar21
Jun21
Sep21
Dec21
Mar22
Jun22
Sep22
Dec22
Mar23
Jun23
Sep23
Dec23
EV-to-EBITDA
0.57
-0.28
-0.31
-0.26
-0.37
Competitive Comparison
For the Biotechnology subindustry, Organovo Holdings's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Organovo Holdings EV-to-EBITDA Distribution
For the Biotechnology industry and Healthcare sector, Organovo Holdings's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Organovo Holdings's EV-to-EBITDA falls into.
Organovo Holdings EV-to-EBITDA Calculation
Organovo Holdings's EV-to-EBITDA for today is calculated as:
Organovo Holdings's current Enterprise Value is $7.90 Mil.
Organovo Holdings's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-19.50 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Organovo Holdings's PE Ratio for today is calculated as:
Organovo Holdings's share price for today is $1.13.
Organovo Holdings's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.170.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.
Thank you for viewing the detailed overview of Organovo Holdings's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.
Organovo Holdings (Organovo Holdings) Business Description
Organovo Holdings Inc is a biotechnology company, which designs and creates functional and three-dimensional human tissues for medical research and therapeutic applications. It also develops and commercializes a platform technology for the generation of three-dimensional human tissues that can be employed in drug discovery and development, biological research, and as therapeutic implants for the treatment of damaged or degenerating tissues and organs. The company collaborates with pharmaceutical and academic partners to develop human biological disease models in three dimensions. Organovo's key instrument platform is the NovoGen Bioprinter. The firm's 3-D bioprinting technologies create tissues using living cells and biocompatible hydrogels.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ONVO has been successfully added to your 